Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Realbotix Q3-2026 results; Nasdaq listing via Onconetix expected by year-end

Aug 12, 2026, 7:34 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Near-term upside hinges on the ONCO RTO closing and Nasdaq listing, which could unlock liquidity and broaden investor access, despite ongoing2026 revenue challenges. Historical analogs show mid-cap microcaps often rally on confirmed listing milestones.

AI summary

What happened, with direct paths to the underlying reporting

Realbotix reported a modest Q3-2026 revenue and continued conversion challenges as it repositions Intima and scales Realbotix. Gross margins and operating costs tightened margins, while the Onconetix reverse merger to Nasdaq could unlock liquidity and elevate valuation, pending closing in Q4 2026.

Q3-2026 revenue: $0.354m; 9M: $0.932m; down YoY.
Intima revenue: Q3 $0.222m, 9M $0.746m; backlogs reshaped.
Gross margins: 24.4% (3Q), 21.0% (9M) vs 37.1%/43.5%.
Operating expenses up to $1.821m (3Q) and $5.33m (9M).
Onconetix merger to list Realbotix LLC on Nasdaq; close expected Q4 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.